Leen Kawas - 18 Oct 2023 Form 3 Insider Report for Eiger BioPharmaceuticals, Inc.

Role
10%+ Owner
Signature
/s/ Leen Kawas
Issuer symbol
N/A
Transactions as of
18 Oct 2023
Net transactions value
$0
Form type
3
Filing time
30 Oct 2023, 16:51:30 UTC
Next filing
02 Nov 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding EIGR Common Stock 1,667,100 18 Oct 2023 See footnote F1, F3
holding EIGR Common Stock 2,700,000 18 Oct 2023 See footnote F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Ms. Kawas controls Propel Bio Management LLC, a Delaware limited liability company ("Propel Management"). Ms. Kawas also shares control of Propel Bio Partners LLC, a Delaware limited liability company ("Propel General Partner"). Ms. Kawas, Propel Management and Propel General Partner act as the investment advisor to, or general partner of, or otherwise provide discretionary advisory services to, one or more private investment funds, and such investment funds directly own 1,667,100 shares of Common Stock.
F2 Propel Management acts as the investment advisor to an investment company registered under the Investment Company Act of 1940, as amended, and such investment company directly owns 2,700,000 shares of Common Stock.
F3 Ms. Kawas expressly disclaims beneficial ownership of the shares of Common Stock reported herein except to the extent of any pecuniary interest.